sangamo therapeutics inc. - SGMO
SGMO
Close Chg Chg %
0.35 0.05 13.15%
Closed Market
0.40
+0.05 (13.15%)
Volume: 9.98M
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: sangamo therapeutics inc. - SGMO
SGMO Key Data
| Open $0.37 | Day Range 0.36 - 0.40 |
| 52 Week Range 0.35 - 1.29 | Market Cap $121.14M |
| Shares Outstanding 336.49M | Public Float 329.25M |
| Beta 1.29 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.44 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 8.05M |
SGMO Performance
| 1 Week | -25.30% | ||
| 1 Month | -9.71% | ||
| 3 Months | -15.22% | ||
| 1 Year | -65.22% | ||
| 5 Years | -97.08% |
SGMO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About sangamo therapeutics inc. - SGMO
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
SGMO At a Glance
Sangamo Therapeutics, Inc.
501 Canal Boulevard
Richmond, California 94084
| Phone | 1-510-970-6000 | Revenue | 57.80M | |
| Industry | Biotechnology | Net Income | -97,941,000.00 | |
| Sector | Health Technology | Employees | 183 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SGMO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.559 |
| Price to Book Ratio | 9.534 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.165 |
| Enterprise Value to Sales | 3.363 |
| Total Debt to Enterprise Value | 0.157 |
SGMO Efficiency
| Revenue/Employee | 315,846.995 |
| Income Per Employee | -535,196.721 |
| Receivables Turnover | 12.571 |
| Total Asset Turnover | 0.427 |
SGMO Liquidity
| Current Ratio | 1.129 |
| Quick Ratio | 1.129 |
| Cash Ratio | 0.915 |
SGMO Profitability
| Gross Margin | 83.804 |
| Operating Margin | -171.509 |
| Pretax Margin | -169.737 |
| Net Margin | -169.448 |
| Return on Assets | -72.379 |
| Return on Equity | -185.394 |
| Return on Total Capital | -183.63 |
| Return on Invested Capital | -118.411 |
SGMO Capital Structure
| Total Debt to Total Equity | 134.238 |
| Total Debt to Total Capital | 57.308 |
| Total Debt to Total Assets | 29.024 |
| Long-Term Debt to Equity | 115.296 |
| Long-Term Debt to Total Capital | 49.222 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Sangamo Therapeutics Inc. - SGMO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 110.70M | 111.30M | 176.23M | 57.80M | |
Sales Growth
| -6.34% | +0.54% | +58.34% | -67.20% | |
Cost of Goods Sold (COGS) incl D&A
| 9.44M | 12.11M | 22.19M | 9.36M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 9.44M | 12.11M | 22.19M | 9.36M | |
Depreciation
| 9.44M | 12.11M | 22.19M | 9.36M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +28.28% | +83.28% | -57.82% | |
Gross Income
| 101.26M | 99.19M | 154.04M | 48.44M | |
Gross Income Growth
| - | -2.05% | +55.30% | -68.55% | |
Gross Profit Margin
| +91.47% | +89.12% | +87.41% | +83.80% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 284.60M | 300.47M | 268.33M | 147.57M | |
Research & Development
| 230.82M | 249.90M | 230.46M | 111.28M | |
Other SG&A
| 53.78M | 50.57M | 37.88M | 36.29M | |
SGA Growth
| +17.57% | +5.58% | -10.70% | -45.00% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 159.71M | 5.86M | - |
EBIT after Unusual Expense
| (183.34M) | (201.28M) | (274.00M) | (105.00M) | |
Non Operating Income/Expense
| 5.35M | 9.43M | 11.10M | 6.89M | |
Non-Operating Interest Income
| 5.35M | 9.43M | 11.10M | 5.86M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (177.99M) | (191.85M) | (262.90M) | (98.11M) | |
Pretax Income Growth
| -47.37% | -7.79% | -37.04% | +62.68% | |
Pretax Margin
| -160.79% | -172.37% | -149.18% | -169.74% | |
Income Tax
| 306.00K | 429.00K | (5.07M) | (167.00K) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| 886.00K | 500.00K | 186.00K | (167.00K) | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | (580.00K) | (71.00K) | (5.26M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (178.30M) | (192.28M) | (257.83M) | (97.94M) | |
Minority Interest Expense
| - | - | - | (11.00K) | - |
Net Income
| (178.29M) | (192.28M) | (257.83M) | (97.94M) | |
Net Income Growth
| -47.35% | -7.85% | -34.09% | +62.01% | |
Net Margin Growth
| -161.05% | -172.76% | -146.30% | -169.45% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (178.29M) | (192.28M) | (257.83M) | (97.94M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (178.29M) | (192.28M) | (257.83M) | (97.94M) | |
EPS (Basic)
| -1.2332 | -1.2458 | -1.478 | -0.4856 | |
EPS (Basic) Growth
| -37.04% | -1.02% | -18.64% | +67.14% | |
Basic Shares Outstanding
| 144.57M | 154.34M | 174.44M | 201.70M | |
EPS (Diluted)
| -1.2332 | -1.2458 | -1.478 | -0.4856 | |
EPS (Diluted) Growth
| -37.04% | -1.02% | -18.64% | +67.14% | |
Diluted Shares Outstanding
| 144.57M | 154.34M | 174.44M | 201.70M | |
EBITDA
| (173.90M) | (189.17M) | (92.10M) | (89.77M) | |
EBITDA Growth
| -40.39% | -8.78% | +51.31% | +2.53% | |
EBITDA Margin
| -157.09% | -169.97% | -52.26% | -155.31% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 3.25 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.062 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.244 | |
| Last Quarter’s Earnings | -0.03 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.309 | Next Fiscal Year Estimate | -0.009 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 4 | 4 |
| Mean Estimate | -0.06 | -0.06 | -0.24 | -0.01 |
| High Estimates | -0.04 | -0.04 | -0.10 | 0.32 |
| Low Estimate | -0.11 | -0.11 | -0.42 | -0.25 |
| Coefficient of Variance | -62.24 | -62.24 | -64.84 | -2,960.39 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Sangamo Therapeutics Inc. - SGMO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Sangamo Therapeutics Inc. - SGMO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 27, 2026 | Nikunj Jain Principal Accounting Officer | 242,996 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share | 97,198.40 |
| Jan 27, 2026 | Prathyusha Durabaibu PRINCIPAL FINANCIAL OFFICER | 660,042 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share | 264,016.80 |
| Jan 27, 2026 | Gregory Davis Head of Research & Technology | 191,062 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share | 76,424.80 |
| Jan 27, 2026 | Scott Willoughby SVP, CHIEF LEGAL OFFICER, SECY | 665,410 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share | 266,164.00 |
| Jan 27, 2026 | Alexander D. Macrae PRESIDENT, CEO AND DIRECTOR; Director | 1,946,584 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share | 778,633.60 |
| Jan 27, 2026 | Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER | 693,128 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.4 per share | 277,251.20 |
| Feb 27, 2025 | Scott Willoughby SVP, GEN. COUNSEL & SECRETARY | 814,842 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Gregory Davis Head of Research & Technology | 99,454 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Gregory Davis Head of Research & Technology | 216,084 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Gregory Davis Head of Research & Technology | 166,358 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.96 per share | 159,703.68 |
| Feb 27, 2025 | Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER | 560,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER | 833,405 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Nathalie Dubois Stringfellow SVP-CHIEF DEVELOPMENT OFFICER | 713,405 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.96 per share | 684,868.80 |
| Feb 27, 2025 | Scott Willoughby SVP, GEN. COUNSEL & SECRETARY | 560,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Scott Willoughby SVP, GEN. COUNSEL & SECRETARY | 694,842 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.96 per share | 667,048.32 |
| Feb 27, 2025 | Prathyusha Durabaibu SVP, CHIEF FINANCIAL OFFICER | 560,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Prathyusha Durabaibu SVP, CHIEF FINANCIAL OFFICER | 811,803 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Prathyusha Durabaibu SVP, CHIEF FINANCIAL OFFICER | 691,803 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.96 per share | 664,130.88 |
| Feb 27, 2025 | Alexander D. Macrae PRESIDENT, CEO AND DIRECTOR; Director | 1,750,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Alexander D. Macrae PRESIDENT, CEO AND DIRECTOR; Director | 2,452,848 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |